What Is a Sodium Polystyrene Sulfonate Enema Used For?

Sodium polystyrene sulfonate (SPS) enema is a rectal treatment for hyperkalemia, the potentially dangerous condition of having too much potassium in the blood. Marketed for decades under the brand name Kayexalate, SPS works by exchanging sodium ions for potassium ions in the gut. The enema form is typically reserved for patients who cannot swallow or tolerate the oral version, but the evidence behind it is surprisingly weak, and the rectal route appears to lower potassium far less effectively than taking SPS by mouth. Understanding what this treatment actually does, when it makes sense, and what can go wrong is worth the effort, because SPS enemas remain widely used in hospitals despite a complicated safety profile.

How the Enema Works Inside the Colon

SPS is a cation-exchange resin. When it reaches the large intestine, the resin swaps sodium ions on its surface for potassium ions in the surrounding intestinal fluid. The potassium is then bound to the resin and excreted in the stool, pulling it out of the body. Each gram of resin can theoretically bind about one milliequivalent (mEq) of potassium, though in practice the exchange is far less efficient. When given as an enema, SPS is typically mixed with water and instilled into the rectum through a tube, then retained for anywhere from 30 minutes to several hours before being expelled or washed out with a cleansing enema.

The colon is where most of the potassium exchange happens regardless of route, so the logic behind the enema is straightforward: deliver the resin directly to where it does its work. In practice, though, contact time matters enormously. Oral SPS travels the entire length of the intestine and spends more time in contact with intestinal fluid, while a rectal dose sits only in the distal colon and rectum and is often expelled before the resin can exchange much potassium.

How Effective Is the Enema Compared to Oral SPS

The short answer is that the enema performs poorly by comparison. In a study evaluating different SPS dosing strategies in hospitalized patients, a 30-gram rectal dose lowered serum potassium by just 0.22 mEq/L, while oral doses of 15, 30, and 60 grams lowered it by 0.39, 0.69, and 0.91 mEq/L respectively. Every single patient who received the enema remained hyperkalemic afterward.¹ That finding is hard to ignore. The rectal route delivered roughly a third of the potassium-lowering effect of the same oral dose, and it failed to normalize potassium in any of the patients who received it.

Broader reviews of resin therapy confirm that SPS lowers potassium in most studies, though the magnitude varies widely depending on the dose, how long treatment continues, and the route. A systematic review found that the vast majority of included studies showed potassium reductions of more than 0.5 mEq/L, but the range across controlled trials was wide, from 0.14 to 1.04 mEq/L compared to placebo.² The one randomized trial specifically designed to test SPS against placebo found that over seven days of oral use, SPS was clearly better at lowering potassium in patients with chronic kidney disease and mild hyperkalemia, with a mean difference of about 1 mEq/L between groups. But a trend toward more electrolyte disturbances and gastrointestinal side effects was also evident.³

The critical point for anyone considering the enema route is that even the oral form of SPS is not considered a good option for acute emergencies. A review in Kidney International noted that SPS is not effective as acute therapy but has shown some benefit when used over a longer period.⁴ The enema, with its shorter contact time and inferior potassium-lowering numbers, is an even weaker candidate for rapid correction of dangerous potassium levels. Hospitals that rely on it in emergencies may be using a tool that works too slowly and too modestly to do the job.

When the Enema Is Still Used

If the enema is so much less effective, why does it persist in clinical practice? The main reason is that some patients simply cannot take anything by mouth. A person who is vomiting, sedated, intubated, has a bowel obstruction above the colon, or has just had upper gastrointestinal surgery may not be a candidate for oral SPS. In those situations, the rectal route is sometimes the only non-intravenous option for trying to pull potassium out through the gut. It also shows up in settings where intravenous therapies like insulin-plus-glucose or calcium gluconate are already on board to shift potassium temporarily into cells, and clinicians want to add a resin to remove potassium from the body entirely, even if the effect is modest.

The enema also carries a significant sodium load, which matters in patients with heart failure. Each standard 15-gram dose of the resin contains a substantial amount of sodium, roughly 60 mEq, because sodium is the ion being traded for potassium. For someone whose heart is already struggling with fluid overload, adding that much sodium rectally can worsen the situation. This trade-off is often overlooked in the rush to treat a dangerously high potassium level.

The FDA Black Box Warning and Intestinal Necrosis

The most alarming risk of SPS, whether oral or rectal, is intestinal necrosis: death of bowel tissue that can be fatal. The U.S. Food and Drug Administration placed a black box warning on SPS, its most serious safety designation, specifically citing cases of intestinal necrosis. The warning notes that bleeding, ischemic colitis, and perforation have all been reported. Many of those cases involved the co-administration of sorbitol, a sweetening and laxative agent that was once routinely mixed with SPS to prevent constipation. The FDA warning explicitly advises against combining SPS with sorbitol.⁵

That same warning lists a long set of conditions that should make clinicians avoid SPS altogether: patients who have not had a bowel movement after surgery, people with a history of chronic constipation, inflammatory bowel disease, ischemic colitis, vascular disease in the gut, previous bowel surgery, or bowel obstruction. In practice, this means many of the sickest patients who are most likely to develop hyperkalemia are also the ones at highest risk from the treatment.

A case series examining intestinal necrosis tied to SPS identified eleven confirmed cases where the timing strongly suggested SPS was the cause. Symptoms appeared as early as three hours and as late as eleven days after administration. Four of those eleven patients died. Contrary to earlier assumptions, only two of the patients were postoperative and only four had end-stage kidney disease, suggesting the risk is not confined to the populations most commonly warned about.⁶ An earlier study looking specifically at postoperative patients who received oral SPS in sorbitol estimated the incidence of intestinal necrosis at about 1.8% in that group, a rate the authors considered high enough to call a “relatively common” complication. No cases of intestinal necrosis were found in a comparison group of over 800 patients who had similar surgeries but did not receive SPS.⁷

When the bowel is injured by SPS, pathologists sometimes find a distinctive pattern. Biopsies from damaged tissue can show purple crystals arranged in a fish-scale appearance, which is the SPS resin itself embedded in the necrotic and inflamed mucosa.⁸ This finding can be the definitive clue that links an episode of colitis or necrosis back to SPS, especially in patients who have multiple risk factors for bowel injury.

Special Risks in Premature Infants

Hyperkalemia is common in very premature newborns, and SPS enemas have been used in neonatal intensive care units. The results have been grim. In one report, four out of twenty premature infants who received SPS enemas developed bloody stools, a rate of 20%. All of the affected infants were younger than 29 weeks of gestation or weighed less than 1,250 grams. Autopsy on one infant revealed extensive vascular congestion and focal hemorrhage in the colon. The authors pointed to the hyperosmolar sorbitol vehicle, measuring over 1,000 mOsm/L, as a likely culprit.⁹

An even more extreme case involved a 650-gram infant born at 24 weeks who developed both cecal impaction and perforation after SPS enemas. X-rays showed the dense resin material physically outlining the infant’s bowel, and pathology confirmed SPS crystals in the abscess. The authors concluded that SPS enemas in infants at that gestational age are probably not helpful for lowering potassium and may actively harm the baby.¹⁰ These reports have led many neonatal units to move away from SPS enemas entirely in very low birth weight infants, though the practice has not disappeared everywhere.

Drug Interactions You Might Not Expect

Because SPS is an ion-exchange resin, it does not just grab potassium. It can bind other positively charged molecules in the gut, including medications. This is a problem whether SPS is given orally or rectally, though the oral route creates more opportunities for interaction because the resin passes through the entire digestive tract.

In vitro testing found that SPS bound some drugs almost completely. Amlodipine, a common blood pressure medication, was reduced to a residual rate of just 3.6% after contact with SPS, meaning the resin absorbed nearly all of it. Nifedipine, another blood pressure drug, was reduced to about 36%. Meanwhile, furosemide, a widely used diuretic, was essentially unaffected.¹¹ A broader in vitro screening of 28 commonly co-prescribed drugs identified 23 potentially new binding interactions with SPS, many of which had not been studied in living patients.¹²

One interaction that has been confirmed in humans involves amitriptyline, a widely prescribed antidepressant. In a crossover study of healthy volunteers, taking SPS at the same time as amitriptyline cut the drug’s absorption by roughly 75%, a reduction large enough to probably make the antidepressant ineffective.¹³ The practical takeaway is that any oral medications should be given at least a few hours apart from oral SPS. With the enema form, the interaction risk is lower but not zero, because some rectal absorption of other drugs could theoretically be affected if they are present in the distal colon.

Newer Alternatives to SPS

SPS was the only FDA-approved potassium-removal agent for decades, which partly explains why it stayed in use despite its safety issues and thin evidence base. That monopoly ended with the approval of two newer drugs: patiromer and sodium zirconium cyclosilicate (SZC, sold as Lokelma). Both were developed specifically to address the shortcomings of SPS.

A systematic review and meta-analysis comparing the newer agents to SPS found that both patiromer and SZC are more selective for potassium, produce a more consistent potassium-lowering effect, and have better adverse-event profiles. SZC stands out for its rapid onset of action, about one hour compared to two to six hours for SPS, making it a more realistic option for acute situations. Patiromer takes longer to start working but appears better tolerated for long-term use, with no reports of serious gastrointestinal adverse effects of the type that plague SPS.¹⁴

In a head-to-head randomized trial of hemodialysis patients, SZC achieved normal potassium levels after about two weeks, while SPS took roughly six weeks to reach the same target. Gastrointestinal side effects occurred in about 5% of the SZC group versus nearly 12% of the SPS group, and patients found SZC significantly more palatable.¹⁵ A larger retrospective comparison in hospitalized patients found that both agents effectively lowered potassium, though SPS actually showed a statistically greater raw reduction. The authors cautioned that dosing variability between the two drugs made direct dose-for-dose comparisons unreliable.¹⁶

Neither patiromer nor SZC has been formulated as an enema, so for the specific clinical scenario where a patient cannot take anything by mouth and IV therapies alone are insufficient, SPS enema remains one of the few options. This is an uncomfortable reality: the rectal route persists partly because the alternatives have not been designed for rectal use.

The Cost Factor

One reason SPS has not been abandoned outright is cost. SPS is cheap, available as a generic, and hospitals have decades of protocols built around it. A cost-utility analysis found that a hypothetical alternative drug would need to cost no more than about $10.77 per daily dose to be considered cost-effective at a standard willingness-to-pay threshold, while at a price of $40 per daily dose, the cost per quality-adjusted life-year gained ballooned to over $26 million. SPS remained the cost-effective option unless the rate of complications from SPS exceeded roughly 20%.¹⁷ Patiromer and SZC are priced considerably higher than generic SPS, which means the switch away from SPS happens faster in well-funded health systems and slower in resource-limited settings, even when the clinical arguments favor the newer agents.

Chronic Use and Unexpected Complications

Most discussions of SPS focus on short-term, in-hospital use, but some patients with chronic kidney disease take it regularly at home to manage persistent hyperkalemia between dialysis sessions. Long-term use introduces its own set of problems. There are case reports of chronic SPS forming masses in the colon that mimic tumors. In one case, a hemodialysis patient on long-term SPS developed a colonic mass that was initially assumed to be cancer. The workup included hospitalization, extensive imaging, and nearly led to surgical removal of a large portion of the colon before the mass was identified as accumulated resin, a pseudotumor rather than a true malignancy. Gastrointestinal symptoms in that patient developed late in the course of treatment rather than early, which is the opposite of the pattern clinicians usually watch for.

Chronic SPS use also raises concerns about electrolyte imbalances beyond potassium. The randomized trial in chronic kidney disease patients showed a trend toward more electrolyte disturbances in the SPS group, including drops in magnesium and calcium, since the resin is not perfectly selective and can exchange other cations along with potassium.¹⁸ For patients on dialysis who already struggle with mineral balance, adding a nonselective ion exchanger can create new problems while solving the original one.